Palisade Bio, Inc.
Palisade Bio, Inc.
Your view on PALI
Overview
What the company does, where it operates, and who runs it.
About Palisade Bio, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- J. D. Finley
- Headquarters
- 5800 Armada Drive, Carlsbad, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- J. D. Finley
- Headquarters
- 5800 Armada Drive, Carlsbad, CA, US
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract.
Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery.
The company was founded in 2005 and is headquartered in Carlsbad, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Palisade Bio, Inc., and the rating behind it. PALI last traded at $2.06; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Palisade Bio, Inc.. Starting points for Palisade Bio, Inc.: EPS -$0.15, beta 1.55 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Palisade Bio, Inc.. Palisade Bio, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Palisade Bio, Inc.. Trailing twelve-month EPS for Palisade Bio, Inc. stands at -$0.15. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Palisade Bio, Inc.. Palisade Bio, Inc. has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Palisade Bio, Inc. valued side by side against its closest peers. Palisade Bio, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Palisade Bio, Inc., and how their positions are changing. At a $357.6M market value, institutional positions materially move Palisade Bio, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Palisade Bio, Inc. executives and directors. Shares of Palisade Bio, Inc. have traded between $0.53 and $3.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Palisade Bio, Inc.. Palisade Bio, Inc. is a $357.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Palisade Bio, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Palisade Bio, Inc.. Coverage tracks Palisade Bio, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.